ARVN - Arvinas stock jumps 30% amid positive data for breast cancer drug
2023-12-06 13:41:44 ET
More on Arvinas
- Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
- Arvinas announces private placement to raise $350M
- Arvinas GAAP EPS of -$1.18 beats by $0.39, revenue of $34.6M misses by $5.45M
- Seeking Alpha’s Quant Rating on Arvinas
- Historical earnings data for Arvinas
For further details see:
Arvinas stock jumps 30% amid positive data for breast cancer drug